Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14088061 | 1.00 | CES2 (0.52) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL508016 | 1.00 | CES2 (0.52) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL1318224 | 1.00 | CES2 (0.52) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL9667227 | 0.84 | CES2 (0.50) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL2812852 | 0.83 | UGT2B7 (0.56) | HDAC4MEN1KMT2AUGT2B7 | |
| SCHEMBL9331659 | 0.83 | UGT2B7 (0.56) | HDAC4MEN1KMT2AUGT2B7 | |
| SCHEMBL9331663 | 0.83 | UGT2B7 (0.56) | HDAC4MEN1KMT2AUGT2B7 | |
| SCHEMBL9334664 | 0.83 | UGT2B7 (0.56) | HDAC4MEN1KMT2AUGT2B7 | |
| SCHEMBL15050759 | 0.83 | CES2 (0.49) | CES2CES1HDAC4HDAC7HDAC5 | |
| SCHEMBL15050756 | 0.83 | CES2 (0.49) | CES2CES1HDAC4HDAC7HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4868344-A | OPTICALLY PURE HALOALCOHOLS | ALDRICH-BORANES, INC. (US) | 1989-09-19 | — | — | US | claimed |
| WO-2025060911-A1 | SUBSTITUTED PYRIDOTRIAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都奥睿药业有限公司 | 2025-03-27 | — | — | WO | disclosed |
| CN-119118931-A | Barbituric acid derivative and preparation method thereof | 武汉绿合医药科技有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118878535-A | Substituted pyridotriazole compound, preparation method and application thereof | 成都奥睿药业有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-110325531-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-110002961-B | Method for racemization-free synthesis of chiral alcohol | 三峡大学 | 2022-05-03 | — | — | CN | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2021-06-10 | — | — | US | disclosed |
| EP-3551626-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2019-10-16 | — | — | EP | disclosed |
| WO-2018106284-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2018-06-14 | — | — | WO | disclosed |
| US-8088780-B2 | 5,7-disubstituted thiazolo[4,5-D]pyrimidines for the selective inhibition of chemokine receptors | ASTRAZENECA AB (SE) | 2012-01-03 | — | — | US | disclosed |
| US-7947693-B2 | 2R)-2-[(2-amino-5-{[(1S)-1-(2-fluorophenyl)ethyl]thio}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]pentan-1-ol; neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases su COPD, asthma | ASTRAZENECA AB (SE) | 2011-05-24 | — | — | US | disclosed |
| US-20110092519-A1 | 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| CN-101193897-B | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives | ASTRAZENECA AB | 2010-12-01 | — | — | CN | disclosed |
| CN-101193898-B | Novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives | ASTRAZENECA AB | 2010-12-01 | — | — | CN | disclosed |
| EP-1869056-B1 | NOVEL 5-SUBSTITUTED 7-AMINO-Ý1,3¨THIAZOLOÝ4,5-D¨PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-11-10 | — | — | EP | disclosed |
| US-20090124637-A1 | Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 | ASTRAZENECA AB (SE) | 2009-05-14 | — | — | US | disclosed |
| US-20080214578-A1 | Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 | ACTURUM REAL ESTATE AB (SE) | 2008-09-04 | — | — | US | disclosed |
| CN-101193898-A | Novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives | ASTRAZENECA AB (SE) | 2008-06-04 | — | — | CN | disclosed |
| CN-101193897-A | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives | ASTRAZENECA AB (SE) | 2008-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092519-A1 | 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS | CX3CR1, CCR2, CXCR3 | CES2 4021/4885CES1 2493/4885HDAC4 4544/4885 |
| US-20080214578-A1 | Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 | CX3CR1, CCR2, CXCR3 | CES2 4565/4885CES1 3121/4885HDAC4 4527/4885 |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | KCND2, SCN1A, CACNA1D | CES2 446/4885CES1 778/4885HDAC4 711/4885 |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | CES2 826/4885CES1 1209/4885HDAC4 1223/4885 |
| US-20090124637-A1 | Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 | CX3CR1, CCR2, CCR5 | CES2 3696/4885CES1 1983/4885HDAC4 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.